Turkish Journal of Oncology Turkish Society for Radiation Oncology
Article Open Access Volume 19 · Issue 4 · 2004 pp. 131–133

SERUM BCL-2 LEVELS IN PATIENTS WITH MALIGNANT MELANOMA

Dr. Derya DURANYILDIZ1, Tıb Bio. Hilal OĞUZ2, Dr. Hakan ÇAMLICA3, Dr. Faruk TAŞ4, Dr. Vildan YASASEVER2, Dr. Erkan TOPUZ5
1 İ.Ü. Onkoloji Enstitüsü Temel Onkoloji ABD, İstanbul
2 İ.Ü. Onkoloji Enstitüsü Temel Onkoloji ABD Kanser Biyokimyası Bilim Dalı, İstanbul
3 İ.Ü.Onkoloji Enstitüsü Prevantif Onkoloji ABD, İstanbul
4 İ.Ü. Onkoloji Enstitüsü Klinik Onkoloji ABD, İstanbul
5 İ.Ü. Onkoloji Enstitüsü
Published: 2004 Pubmed: 70228 Article ID: 645
PDF
Abstract
We investigated the serum levels of an important protein, bcl-2, in 44 patients with malignant melanoma and the relationship with tumour progression and known prognostic parameters. Serum bcl-2 levels were determined using enzyme-linked immunosorbent assay (ELISA) (Biosource International, Inc. 542 Flynn Road Camarillo, California, USA). The baseline serum bcl-2 levels were significantly higher in patients with malignant melanoma than in the control group (p=0,01). The bcl-2 values were not changed with Interferon-alfa therapy (n=8) and chemotherapy (n=10).With this small study, it is not possible to determine the value of serum levels of bcl-2 in malignant melanoma and larger scale research studies are needed in this field.

Keywords: malignant melanoma, bcl-2, serum

Previous article Next article

Article information

5,889 Views
1,594 Downloads
View / Download PDF

Current Issue Vol 19 · Iss 4

Turkish Journal of Oncology – Issue cover
Submit manuscript
Most read & early access
Click an article to open abstract.
No early access articles.
View all articles